Microplasmin receives orphan drug protection

Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.

Related Content:

Pediatrics

It takes a village to beat visual system diseases in children

Gene therapy surgical pearls for successful outcomes

Looking to the future of pediatric ophthalmology